Reported benefits (per available research): Studied for its ability to trigger strong, dose-dependent endogenous growth hormone release, with some human research indicating it releases more GH than growth hormone releasing hormone (GHRH) alone Investigated for potential cardioprotective effects through CD36 receptor binding in cardiac tissue, with preclinical and small experimental work describing improved cardiac function after ischemia, though researchers note clinical trials in humans remain limited May support lean mass, strength, and connective-tissue recovery, a claim attributed to GH/IGF-1-driven protein synthesis rather than to dedicated human bodybuilding trials Explored in preclinical, cell-based research for neuroprotective and antioxidant activity, evidence that is preliminary and non-human Known risks and side effects: Acute elevation of ACTH and cortisol, documented in a small human study, raising theoretical concern about HPA-axis disruption or Cushingoid effects with sustained high-dose exposure Elevated prolactin reported in human research, which in chronic excess is associated with hyperprolactinemia-related effects such as visual disturbance and reproductive or hormonal disruption Water retention, joint discomfort, and increased appetite, effects consistent with other GH-elevating secretagogues Partial, reversible desensitization of the GH response with prolonged daily use in human studies, with sensitivity reported to return after a period off Because it is distributed only as an unregulated research chemical, actual product purity and dosage are unverified, adding contamination and dosing-error risk on top of any physiological effects Evidence snapshot: The strongest human data is a small 1999 clinical study (15 healthy male volunteers) confirming hexarelin's stimulatory effect on GH, ACTH, and cortisol via the HPA axis
Separations 9(11):331 Antonelli A, Fallahi P, Elia G, Ragusa F, Paparo SR, Ruffilli I, Patrizio A, Gonnella D, Giusti C, Virili C (2020) Graves disease: clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy
Fisher M, Petrie MC, Ambery PD, Donaldson J, Ye J, McMurray JJ
Ann Endocrinol (Paris)
This pricing transparency allows patients to focus on clinical outcomes rather than financial anxiety
But they could find this amount doesnt give them the rate of weight loss they want, and so feel as though they have to increase the strength of their pen
